Related Experiment Video
Updated: Mar 30, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Anti-tumor effect of RGD modified PTX loaded liposome on prostatic cancer
Yunjie Cao1, Yaojun Zhou1, Qianfeng Zhuang1
1Department of Urology, Third Affiliated Hospital of Soochow University Changzhou 213003, China.
Abstract:
In this study, we report an active targeting liposomal formulation directed by a novel peptide (RGD) that specifically binds to the integrins receptors overexpressed on prostatic cancer cells. The objectives of this study were to evaluate the in vitro and in vivo tumor drug targeting delivery of RGD modified liposomes on PC-3 cells and DU145 cells. The uptake efficiency of RGD-LP was 5.2 times higher than that of LP on PC-3 cells. The uptake efficiency of RGD-LP was 3.2 times higher than that of LP on DU145 cells. The anti-proliferative activity of RGD-LP-PTX against PC-3 cells and DU145 cells were much stronger compared to that of LP-PTX and free PTX, respectively. The tumor spheroids experiment revealed that RGD-LP-PTX was more efficaciously internalized into tumor spheroids than LP in both PC-3 cells and DU145 cells. Compared to LP-PTX and free PTX, RGD-LP-PTX showed the greatest tumor growth inhibitory effect in vivo. In brief, the RGD-LP may be an efficient targeting drug delivery system for prostatic cancer.
Insights
This study introduces RGD-modified liposomes (RGD-LP) for targeted prostate cancer drug delivery. RGD-LP significantly enhances drug uptake and anti-cancer activity in vitro and in vivo.
Area of Science:
- Nanotechnology
- Oncology
- Drug Delivery Systems
Background:
- Prostate cancer is a significant health concern.
- Targeted drug delivery aims to improve therapeutic efficacy and reduce side effects.
- Integrin receptors are overexpressed on prostate cancer cells.
Purpose of the Study:
- To develop and evaluate an active targeting liposomal formulation using a novel peptide (RGD) for prostate cancer.
- To assess the in vitro and in vivo tumor drug targeting delivery of RGD-modified liposomes (RGD-LP) on PC-3 and DU145 cells.
- To investigate the anti-proliferative and tumor growth inhibitory effects of RGD-LP loaded with paclitaxel (PTX).
Main Methods:
- Preparation of RGD-modified liposomes (RGD-LP) and non-modified liposomes (LP).
- Evaluation of cellular uptake efficiency of RGD-LP and LP on PC-3 and DU145 cells.
- Assessment of anti-proliferative activity of RGD-LP-PTX, LP-PTX, and free PTX in vitro.
- Tumor spheroids experiments to evaluate internalization of RGD-LP-PTX.
- In vivo studies to determine the tumor growth inhibitory effect of RGD-LP-PTX compared to controls.
Main Results:
- RGD-LP showed significantly higher uptake efficiency than LP in both PC-3 (5.2-fold) and DU145 (3.2-fold) cells.
- RGD-LP-PTX exhibited stronger anti-proliferative activity against PC-3 and DU145 cells than LP-PTX and free PTX.
- RGD-LP-PTX demonstrated superior internalization into tumor spheroids.
- In vivo, RGD-LP-PTX achieved the greatest tumor growth inhibition compared to LP-PTX and free PTX.
Conclusions:
- RGD-modified liposomes effectively target prostate cancer cells overexpressing integrin receptors.
- RGD-LP represents a promising and efficient drug delivery system for enhanced prostate cancer therapy.
- The RGD peptide modification significantly improves the therapeutic potential of liposomal drug delivery for prostate cancer.
